Artia Global Partners LP reported 46 positions worth $525.43M for the quarter ended Jun 30, 2026, up 20.9% on the prior quarter. It opened 6 new positions, added to 11, trimmed 3 and exited 4. Its largest holding is Abivax S.A. at 13.1% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| BTSG BrightSpring Health Services, Inc. | +463.5K | +861.6% | $32.33M | 6.87% |
| ALKS Alkermes plc. | +449.0K | – | $23.52M | 4.48% |
| TVTX Travere Therapeutics, Inc. | +268.3K | +379.5% | $15.24M | 3.67% |
| RVMD Revolution Medicines, Inc. | +60.4K | +48.3% | $11.31M | 6.61% |
| GH Guardant Health, Inc. | +38.1K | – | $5.72M | 1.09% |
| ABSI Absci Corp | +464.4K | – | $5.38M | 1.02% |
| DGX Quest Diagnostics Inc | +24.3K | +59.5% | $5.15M | 2.63% |
| CYTK Cytokinetics Inc | +54.4K | +333.7% | $4.63M | 1.15% |
| CELC Celcuity Inc. | +43.7K | +280.8% | $4.58M | 1.18% |
| TRVI Trevi Therapeutics, Inc. | +197.3K | +9.8% | $3.68M | 7.85% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| LLY ELI LILLY & Co | -38.2K | -100.0% | $35.15M | Exited |
| ABVX Abivax S.A. | -84.3K | -14.0% | $11.23M | 13.1% |
| INSM INSMED Inc | -39.7K | -6.3% | $4.23M | 11.95% |
| ABBV AbbVie Inc. | -14.5K | -100.0% | $3.15M | Exited |
| BBIO BridgeBio Pharma, Inc. | -20.4K | -100.0% | $1.51M | Exited |
| ALMS Alumis Inc. | -46.5K | -14.3% | $1.31M | 1.49% |
| AVTX Avalo Therapeutics, Inc. | -29.0K | -100.0% | $432.52K | Exited |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| ALKS Alkermes plc. | +449.0K | $23.52M | 4.48% |
| GH Guardant Health, Inc. | +38.1K | $5.72M | 1.09% |
| ABSI Absci Corp | +464.4K | $5.38M | 1.02% |
| ORKA Oruka Therapeutics, Inc. | +33.4K | $3.18M | 0.605% |
| CMPX Compass Therapeutics, Inc. | +383.2K | $839.21K | 0.16% |
| SYRE Spyre Therapeutics, Inc. | +4,000 | $355.12K | 0.068% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ABVX Abivax S.A. | Healthcare | 516.4K | $68.82M | 13.1% | -84.3K | -14.0% | Reduced | 0.74% |
| 2 | INSM INSMED Inc | Healthcare | 589.1K | $62.80M | 11.95% | -39.7K | -6.3% | Reduced | 0.27% |
| 3 | TRVI Trevi Therapeutics, Inc. | Healthcare | 2.21M | $41.23M | 7.85% | +197.3K | +9.8% | Added | 1.41% |
| 4 | BTSG BrightSpring Health Services, Inc. | Healthcare | 517.3K | $36.08M | 6.87% | +463.5K | +861.6% | Added | 0.25% |
| 5 | RVMD Revolution Medicines, Inc. | Healthcare | 185.4K | $34.72M | 6.61% | +60.4K | +48.3% | Added | 0.09% |
| 6 | ARGX Argenx Se | Healthcare | 29.7K | $27.59M | 5.25% | 0 | 0.0% | Unchanged | 0.05% |
| 7 | ALKS Alkermes plc. | Healthcare | 449.0K | $23.52M | 4.48% | +449.0K | – | New | 0.27% |
| 8 | TVTX Travere Therapeutics, Inc. | Healthcare | 339.0K | $19.26M | 3.67% | +268.3K | +379.5% | Added | 0.36% |
| 9 | AZN Astrazeneca Plc | Healthcare | 98.4K | $18.65M | 3.55% | +3,000 | +3.1% | Added | 0.01% |
| 10 | NAMS NewAmsterdam Pharma Co N.V. | Healthcare | 503.9K | $17.08M | 3.25% | 0 | 0.0% | Unchanged | 0.41% |
| 11 | DNTH Dianthus Therapeutics, Inc. | Healthcare | 163.0K | $15.89M | 3.02% | 0 | 0.0% | Unchanged | 0.29% |
| 12 | DGX Quest Diagnostics Inc | Healthcare | 65.1K | $13.80M | 2.63% | +24.3K | +59.5% | Added | 0.06% |
| 13 | IONS Ionis Pharmaceuticals Inc | Healthcare | 144.4K | $11.45M | 2.18% | 0 | 0.0% | Unchanged | 0.09% |
| 14 | EYPT EyePoint, Inc. | Healthcare | 767.1K | $10.97M | 2.09% | 0 | 0.0% | Unchanged | 0.89% |
| 15 | ALMS Alumis Inc. | Healthcare | 278.5K | $7.84M | 1.49% | -46.5K | -14.3% | Reduced | 0.22% |
Tip. Select a row to see that position’s full history at Artia Global Partners.
As of its Q2 2026 13F filing, Artia Global Partners LP’s five largest positions were Abivax S.A. (ABVX) at 13.1%, INSMED Inc (INSM) at 12.0%, Trevi Therapeutics, Inc. (TRVI) at 7.8%, BrightSpring Health Services, Inc. (BTSG) at 6.9%, Revolution Medicines, Inc. (RVMD) at 6.6% of the reported portfolio.
Artia Global Partners LP reported a 13F portfolio worth $525.43M across 46 positions for Q2 2026. That is up 20.9% from the previous quarter.
Its largest purchases by value were BrightSpring Health Services, Inc. ($32.33M), Alkermes plc. ($23.52M), Travere Therapeutics, Inc. ($15.24M). It opened 6 new positions.
Its largest sales by value were ELI LILLY & Co ($35.15M), Abivax S.A. ($11.23M), INSMED Inc ($4.23M). It exited 4 positions entirely.
From the Form 13F-HR reports Artia Global Partners LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.